{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:02:48Z","timestamp":1778713368000,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY20C120001"],"award-info":[{"award-number":["LY20C120001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.taap.2023.116674","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:22:02Z","timestamp":1693268522000},"page":"116674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Valbenazine promotes body growth via growth hormone signaling during zebrafish embryonic development"],"prefix":"10.1016","volume":"477","author":[{"given":"Zhengkang","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziru","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengqing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqian","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116674_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2019.11.021","article-title":"Valbenazine-induced parkinsonism","volume":"70","author":"Akbar","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.taap.2023.116674_bb0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/bs.ctdb.2016.10.007","article-title":"Zebrafish in toxicology and environmental health","volume":"124","author":"Bambino","year":"2017","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.taap.2023.116674_bb0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrendo.2015.165","article-title":"Short and tall stature: a new paradigm emerges","volume":"11","author":"Baron","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.taap.2023.116674_bb0020","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13725","article-title":"Vesicular monoamine transporter 2 (SLC18A2) regulates monoamine turnover and brain development in zebrafish","volume":"234","author":"Baronio","year":"2022","journal-title":"Acta Physiol (Oxford)"},{"key":"10.1016\/j.taap.2023.116674_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12634","article-title":"Vesicular monoamine transporter 2 mediates fear behavior in mice","volume":"19","author":"Branco","year":"2020","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.taap.2023.116674_bb0030","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s00213-021-05950-4","article-title":"Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns","volume":"238","author":"Carratala-Ros","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.taap.2023.116674_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/acs.chemrestox.9b00335","article-title":"Use of zebrafish in drug discovery toxicology","volume":"33","author":"Cassar","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.taap.2023.116674_bb0040","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","article-title":"Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature","volume":"34","author":"Chen","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.taap.2023.116674_bb0045","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1096\/fj.00-0817rev","article-title":"The vesicular neurotransmitter transporters: current perspectives and future prospects","volume":"14","author":"Eiden","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.taap.2023.116674_bb0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14737175.2021.1898948","article-title":"Clinical development of valbenazine for tics associated with Tourette syndrome","volume":"21","author":"Farber","year":"2021","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.taap.2023.116674_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pharmthera.2016.03.009","article-title":"Advancements in zebrafish applications for 21st century toxicology","volume":"161","author":"Garcia","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.taap.2023.116674_bb0060","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/pr.114.010397","article-title":"Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease","volume":"67","author":"German","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.taap.2023.116674_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12958-020-00677-x","article-title":"Growth hormone activates PI3K\/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome","volume":"18","author":"Gong","year":"2020","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.taap.2023.116674_bb0070","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5603\/PJNNS.a2019.0052","article-title":"Antipsychotic drugs in epilepsy","volume":"53","author":"Gorska","year":"2019","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.taap.2023.116674_bb0075","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.116.239160","article-title":"Pharmacologic characterization of Valbenazine (NBI-98854) and its metabolites","volume":"361","author":"Grigoriadis","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2023.116674_bb0080","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of Valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.taap.2023.116674_bb0085","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1523\/JNEUROSCI.2551-14.2015","article-title":"Circadian modulation of dopamine levels and dopaminergic neuron development contributes to attention deficiency and hyperactive behavior","volume":"35","author":"Huang","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.taap.2023.116674_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172872","article-title":"Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: relevance to tardive dyskinesia and antipsychotic action","volume":"190","author":"Huang","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.taap.2023.116674_bb0095","first-page":"61","article-title":"Long-term safety and tolerability of Valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder","volume":"47","author":"Josiassen","year":"2017","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.taap.2023.116674_bb0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40265-017-0770-9","article-title":"Valbenazine: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2023.116674_bb0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00007256-198704020-00004","article-title":"Growth hormone and athletes","volume":"4","author":"Macintyre","year":"1987","journal-title":"Sports Med."},{"key":"10.1016\/j.taap.2023.116674_bb0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bbi.2020.12.029","article-title":"Ghrelin modulates dopaminergic neuron formation and attention deficit hyperactivity disorder-like behaviors: from animals to human models","volume":"94","author":"Shi","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.taap.2023.116674_bb0115","first-page":"1","article-title":"Human growth hormone","volume":"46","author":"Strobl","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.taap.2023.116674_bb0120","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/JCP.0b013e3182524393","article-title":"Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia","volume":"32","author":"Sugai","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.taap.2023.116674_bb0125","doi-asserted-by":"crossref","first-page":"9938","DOI":"10.1073\/pnas.94.18.9938","article-title":"VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity","volume":"94","author":"Takahashi","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2023.116674_bb0130","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4149\/neo_2020_200108N26","article-title":"miR-497 inhibits tumor growth and migration of osteosarcoma by targeting plexinA4 and CDK6","volume":"67","author":"Tian","year":"2020","journal-title":"Neoplasma"},{"key":"10.1016\/j.taap.2023.116674_bb0135","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2146\/news170031","article-title":"Valbenazine approved for treatment of tardive dyskinesia","volume":"74","author":"Traynor","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.taap.2023.116674_bb0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13041-021-00875-7","article-title":"VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder","volume":"14","author":"Valli","year":"2021","journal-title":"Mol. Brain"},{"key":"10.1016\/j.taap.2023.116674_bb0145","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.bbrc.2016.01.079","article-title":"Vesicular monoamine transporter 2 (Vmat2) knockdown elicits anxiety-like behavior in zebrafish","volume":"470","author":"Wang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2023.116674_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2020.110820","article-title":"Role of GH\/IGF axis in arsenite-induced developmental toxicity in zebrafish embryos","volume":"201","author":"Wang","year":"2020","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"10.1016\/j.taap.2023.116674_bb0155","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1152\/ajpendo.00227.2017","article-title":"Different physiological roles of insulin receptors in mediating nutrient metabolism in zebrafish","volume":"315","author":"Yang","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.taap.2023.116674_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2021.126142","article-title":"Physiological and transcriptomic changes of zebrafish (Danio rerio) embryos-larvae in response to 2-MIB exposure","volume":"416","author":"Zhou","year":"2021","journal-title":"J. Hazard. Mater."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23003137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23003137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T13:40:37Z","timestamp":1726062037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23003137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":32,"alternative-id":["S0041008X23003137"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116674","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valbenazine promotes body growth via growth hormone signaling during zebrafish embryonic development","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116674"}}